Montecalvo Antonio S. 4

What Happened
Antonio Montecalvo, Vice President, Health Policy at Organogenesis (ORGO), received a combination of equity awards on February 18, 2026 totaling 75,005 shares (40,625 RSUs + 11,218 RSUs + 23,162 performance-settled shares). These grants were reported at $0.00 per share (award/vesting). On the same date 3,741 shares were disposed of at $3.84 each to satisfy tax withholding obligations (proceeds ≈ $14,365). Overall this is an award/vesting event (net acquisition of equity) with a routine withholding-related disposition.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (appears timely).
• Awards received (all reported as $0.00 acquisition price): 40,625 RSUs; 11,218 RSUs; 23,162 shares issued on settlement of a 2025 performance award — total 75,005.
• Shares withheld for taxes: 3,741 shares disposed at $3.84 each = $14,365 (transaction code F = tax withholding).
• Footnotes of note:
  • F1: The RSUs represent the contingent right to one share each and vest in equal annual installments over four years beginning Feb 15, 2026.
  • F2: 23,162 shares were issued upon vesting/settlement of a 2025 performance share award tied to performance milestones.
  • F3: (Referenced in filing) an option becomes exercisable in equal annual installments over four years beginning Feb 15, 2026.
• Shares owned after the transactions were not specified in the excerpt of the filing.

Context

• The main event is award/vesting of equity (positive/neutral signal for ownership) rather than a market sale; the small disposition was a routine tax-withholding sale, not an open-market sell.
• For retail investors: award grants increase insider ownership over time as the RSUs/earned performance shares vest; the withheld shares simply cover taxes and are common in equity compensation.
• No 10b5-1 plan, late-filing flag, or other trading-plan information was disclosed in the provided filing excerpt.